Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Tan

Showing results (621-630 of 641) with videos related to

Pageof 65
Sort By:
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
JAMA Surgery|May 7, 2025
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical TrialMark Basik, Reena S Cecchini, Jennifer F De Los Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
Cancer Chemotherapy and Pharmacology|August 10, 2010
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesPaula M Fracasso, Kerry J Williams, Ronald C Chen, et al.
The Lancet Regional Health. Southeast Asia|April 23, 2026
Burden and risk factors of influenza-associated acute respiratory infections among older adults in India: a multicentric community-based surveillance (2018-2023)Prabu Rajkumar, Girish Kumar Chethrapilly Purushothaman, Ritvik Amarchand, et al.
The Oncologist|August 28, 2016
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersKim M Hirshfield, Denis Tolkunov, Hua Zhong, et al.
Pageof 65

Showing results (621-630 of 641) with videos related to

Sort By:
Pageof 65
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
JAMA Surgery|May 7, 2025
Breast Tumor-Bed Biopsy for Pathological Complete Response Prediction: The NRG-BR005 Nonrandomized Clinical TrialMark Basik, Reena S Cecchini, Jennifer F De Los Santos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated AnalysisEric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenanceRoss S Firestone, Anish K Simhal, Devin McAvoy, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Robust CD4<sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelEric M Jurgens, Sneha Mitra, Kevin Herrera, et al.
Journal of Hepatology|August 14, 2025
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinomaTim Meyer, Richard S Finn, Mitesh Borad, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
Cancer Chemotherapy and Pharmacology|August 10, 2010
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignanciesPaula M Fracasso, Kerry J Williams, Ronald C Chen, et al.
The Lancet Regional Health. Southeast Asia|April 23, 2026
Burden and risk factors of influenza-associated acute respiratory infections among older adults in India: a multicentric community-based surveillance (2018-2023)Prabu Rajkumar, Girish Kumar Chethrapilly Purushothaman, Ritvik Amarchand, et al.
The Oncologist|August 28, 2016
Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersKim M Hirshfield, Denis Tolkunov, Hua Zhong, et al.
Pageof 65